2022
DOI: 10.3233/jpd-223349
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of Olfactory Tract Diffusion Measures Between Early Stage Parkinson’s Disease Patients and Healthy Controls Using Ultra-High Field MRI

Abstract: Background: MRI is a valuable method to assist in the diagnostic work-up of Parkinson’s disease (PD). The olfactory tract (OT) has been proposed as a potential MRI biomarker for distinguishing PD patients from healthy controls. Objective: This study aims to further investigate whether diffusion measures of the OT differ between early stage PD patients and healthy controls. Methods: Twenty hyposmic/anosmic PD patients, 65 normosmic PD patients, and 36 normosmic healthy controls were evaluated and a 7T diffusion… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 42 publications
0
2
0
Order By: Relevance
“…On the other hand, atrophy, and changes in the structural integrity of OT has been also observed in PD subjects with respect to controls [ 13 ]. Besides, OT MRI diffusion measures are not adequate as early clinical biomarker for PD [ 14 ]. OT volume is smaller in PD than other movement disorders, such as Multiple system atrophy (MSA), Progressive supranuclear palsy (PSP), and Corticobasal degeneration (CBD) [ 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, atrophy, and changes in the structural integrity of OT has been also observed in PD subjects with respect to controls [ 13 ]. Besides, OT MRI diffusion measures are not adequate as early clinical biomarker for PD [ 14 ]. OT volume is smaller in PD than other movement disorders, such as Multiple system atrophy (MSA), Progressive supranuclear palsy (PSP), and Corticobasal degeneration (CBD) [ 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, atrophy, and changes in the structural integrity of OT has been also observed in PD subjects with respect to controls [13]. Besides, OT MRI diffusion measures are not adequate as early clinical biomarker for PD [14]. OT volume is smaller in PD than PD-related disorders such as Multiple system atrophy (MSA), Progressive supranuclear palsy (PSP), and Corticobasal degeneration (CBD) [15].…”
Section: Introductionmentioning
confidence: 99%